UNIVERSI
TÄ
TS-
BIBLIOTHEK
P
ADERBORN
Anmelden
Menü
Menü
Start
Hilfe
Blog
Weitere Dienste
Neuerwerbungslisten
Fachsystematik Bücher
Erwerbungsvorschlag
Bestellung aus dem Magazin
Fernleihe
Einstellungen
Sprache
Deutsch
Deutsch
Englisch
Farbschema
Hell
Dunkel
Automatisch
Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist
gegebenenfalls
nur via VPN oder Shibboleth (DFN-AAI) möglich.
mehr Informationen...
Universitätsbibliothek
Katalog
Suche
Details
Zur Ergebnisliste
Ergebnis 7 von 28
Datensatz exportieren als...
BibTeX
Detecting drug resistance in pancreatic cancer organoids guides optimized chemotherapy treatment
The Journal of pathology, 2022-08, Vol.257 (5), p.607-619
Hennig, Alexander
Baenke, Franziska
Klimova, Anna
Drukewitz, Stephan
Jahnke, Beatrix
Brückmann, Sascha
Secci, Ramona
Winter, Christof
Schmäche, Tim
Seidlitz, Therese
Bereuter, Jean‐Paul
Polster, Heike
Eckhardt, Lisa
Schneider, Sidney A
Brückner, Stefan
Schmelz, Renate
Babatz, Jana
Kahlert, Christoph
Distler, Marius
Hampe, Jochen
Reichert, Maximilian
Zeißig, Sebastian
Folprecht, Gunnar
Weitz, Jürgen
Aust, Daniela
Welsch, Thilo
Stange, Daniel E
2022
Volltextzugriff (PDF)
Details
Autor(en) / Beteiligte
Hennig, Alexander
Baenke, Franziska
Klimova, Anna
Drukewitz, Stephan
Jahnke, Beatrix
Brückmann, Sascha
Secci, Ramona
Winter, Christof
Schmäche, Tim
Seidlitz, Therese
Bereuter, Jean‐Paul
Polster, Heike
Eckhardt, Lisa
Schneider, Sidney A
Brückner, Stefan
Schmelz, Renate
Babatz, Jana
Kahlert, Christoph
Distler, Marius
Hampe, Jochen
Reichert, Maximilian
Zeißig, Sebastian
Folprecht, Gunnar
Weitz, Jürgen
Aust, Daniela
Welsch, Thilo
Stange, Daniel E
Titel
Detecting drug resistance in pancreatic cancer organoids guides optimized chemotherapy treatment
Ist Teil von
The Journal of pathology, 2022-08, Vol.257 (5), p.607-619
Ort / Verlag
Chichester, UK: John Wiley & Sons, Ltd
Erscheinungsjahr
2022
Quelle
Wiley Online Library - AutoHoldings Journals
Beschreibungen/Notizen
Drug combination therapies for cancer treatment show high efficacy but often induce severe side effects, resulting in dose or cycle number reduction. We investigated the impact of neoadjuvant chemotherapy (neoCTx) adaptions on treatment outcome in 59 patients with pancreatic ductal adenocarcinoma (PDAC). Resections with tumor‐free margins were significantly more frequent when full‐dose neoCTx was applied. We determined if patient‐derived organoids (PDOs) can be used to personalize poly‐chemotherapy regimens by pharmacotyping of treatment‐naïve and post‐neoCTx PDAC PDOs. Five out of ten CTx‐naïve PDO lines exhibited a differential response to either the FOLFIRINOX or the Gem/Pac regimen. NeoCTx PDOs showed a poor response to the neoadjuvant regimen that had been administered to the respective patient in 30% of cases. No significant difference in PDO response was noted when comparing modified treatments in which the least effective single drug was removed from the complete regimen. Drug testing of CTx‐naïve PDAC PDOs and neoCTx PDOs may be useful to guide neoadjuvant and adjuvant regimen selection, respectively. Personalizing poly‐chemotherapy regimens by omitting substances with low efficacy could potentially result in less severe side effects, thereby increasing the fraction of patients receiving a full course of neoadjuvant treatment. © 2022 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.
Sprache
Englisch
Identifikatoren
ISSN: 0022-3417
eISSN: 1096-9896
DOI: 10.1002/path.5906
Titel-ID: cdi_proquest_miscellaneous_2646943469
Format
–
Schlagworte
Adenocarcinoma
,
Adenocarcinoma - pathology
,
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
,
Carcinoma, Pancreatic Ductal - drug therapy
,
Carcinoma, Pancreatic Ductal - pathology
,
Chemotherapy
,
Drug dosages
,
Drug Resistance
,
Humans
,
Neoadjuvant Therapy
,
Organoids
,
Organoids - pathology
,
Pancreatic cancer
,
Pancreatic Neoplasms
,
Pancreatic Neoplasms - drug therapy
,
Pancreatic Neoplasms - pathology
,
Patients
,
patient‐derived organoids
,
personalized medicine
,
Side effects
,
treatment response
,
Tumors
Weiterführende Literatur
Empfehlungen zum selben Thema automatisch vorgeschlagen von
bX